| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom and 2 Central Pathology Laboratory, Department of Histopathology, St. James's Hospital, Dublin, Ireland
Requests for reprints: Joanne Edwards, Endocrine Cancer Group, University Department of Surgery, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Level II, Queen Elizabeth Building, Glasgow G31 2ER, United Kingdom. Phone: 44-141-211-5441; Fax: 44-141-552-3229; E-mail: je10b{at}clinmed.gla.ac.uk.
Purpose: The role of the type I receptor tyrosine kinase (HER) family in progression of prostate cancer is controversial. Breast cancer studies show that these receptors should be investigated as a family. The current study investigates expression of HER1-HER4 and EGFRvIII in matched hormone-sensitive and hormone-refractory prostate tumors.
Experimental Design: Immunohistochemical analysis was used to investigate protein expression of HER1-HER4, EGFRvIII, and phosphorylated Akt (pAkt) in matched hormone-sensitive and hormone-refractory prostate tumors.
Results: Surprisingly, high HER2 membrane expression in hormone-sensitive tumors was associated with an increased time to biochemical relapse (P = 0.0003), and this translated into longer overall survival (P = 0.0021). Consistent with other studies, HER4 membrane expression in hormone-sensitive tumors was associated with longer time to biochemical relapse (P = 0.042), and EGFRvIII membrane expression was associated with shorter time to biochemical relapse (P = 0.015). An increase in pAkt expression was associated with reduced survival (P = 0.0098). Multivariate analysis showed that HER2 was an independent positive predictive marker of time to relapse in hormone-sensitive prostate tumors (P = 0.014). In contrast, high HER2 expression in hormone-refractory tumors was associated with decreased time to death from biochemical relapse (P = 0.039), and EGFRvIII nuclear expression was associated with decreased time to death from biochemical relapse and decreased overall survival (P = 0.02 and P = 0.005).
Conclusion: These results suggest that the HER family may have multiple roles in prostate cancer, and that expression of the proteins alone is insufficient to predict the biological response that they may elicit.
This article has been cited by other articles:
|
|
 |
|
  S. R. Chinni, H. Yamamoto, Z. Dong, A. Sabbota, R. D. Bonfil, and M. L. Cher CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone Mol. Cancer Res., March 1, 2008; 6(3): 446 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. de la Iglesia, G. Konopka, S. V. Puram, J. A. Chan, R. M. Bachoo, M. J. You, D. E. Levy, R. A. DePinho, and A. Bonni Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway Genes & Dev., February 15, 2008; 22(4): 449 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Domingo-Domenech, P. L. Fernandez, X. Filella, A. Martinez-Fernandez, R. Molina, E. Fernandez, A. Alcaraz, J. Codony, P. Gascon, and B. Mellado Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel Ann. Onc., February 1, 2008; 19(2): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Diallo, A. Aldejmah, A. F. Mouhim, B. Peant, M. A. Fahmy, I. H. Koumakpayi, K. Sircar, L. R. Begin, A.-M. Mes-Masson, and F. Saad NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model Clin. Cancer Res., December 1, 2007; 13(23): 7044 - 7052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. V.L. Hayes, E. Blackburn, L. V. Smart, M. M. Boyle, G. A. Russell, T. M. Frost, B. J.T. Morgan, A. J. Baines, and W. J. Gullick Identification and Characterization of Novel Spliced Variants of Neuregulin 4 in Prostate Cancer Clin. Cancer Res., June 1, 2007; 13(11): 3147 - 3155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H. Koumakpayi, J.-S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. R. Begin, A.-M. Mes-Masson, and F. Saad Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2730 - 2737. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
